Jason Hoitt - Stoke Therapeutics Chief Officer
| STOK Stock | USD 11.91 0.14 1.19% |
Executive
Jason Hoitt is Chief Officer of Stoke Therapeutics
| Age | 46 |
| Address | 45 Wiggins Avenue, Bedford, MA, United States, 01730 |
| Phone | 781 430 8200 |
| Web | https://www.stoketherapeutics.com |
Stoke Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.275) % which means that it has lost $0.275 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5206) %, meaning that it created substantial loss on money invested by shareholders. Stoke Therapeutics' management efficiency ratios could be used to measure how well Stoke Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.48. Return On Capital Employed is expected to rise to -0.55 this year. At this time, Stoke Therapeutics' Non Current Liabilities Total is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 5.1 M this year, although the value of Total Current Liabilities will most likely fall to about 15.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Emily Pimblett | Eliem Therapeutics | 40 | |
| MD FAAP | Lumos Pharma | N/A | |
| Caroline MD | Ikena Oncology | 52 | |
| JD Esq | Seres Therapeutics | 69 | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Bob Lally | Ikena Oncology | N/A | |
| David MS | Ikena Oncology | N/A | |
| Nicole Esq | HCW Biologics | N/A | |
| Samuel MD | Tempest Therapeutics | 58 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Lindsay Young | Tempest Therapeutics | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| John PharmD | Scpharmaceuticals | N/A | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| Ryan Witt | RenovoRx | N/A | |
Management Performance
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.28 |
Stoke Therapeutics Leadership Team
Elected by the shareholders, the Stoke Therapeutics' board of directors comprises two types of representatives: Stoke Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stoke. The board's role is to monitor Stoke Therapeutics' management team and ensure that shareholders' interests are well served. Stoke Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stoke Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Jonathan JD, Corporate Counsel | ||
| Shamim MS, Senior Officer | ||
| FACC MD, Chief Officer | ||
| Joan Wood, Chief Officer | ||
| Dawn Kalmar, Chief Officer | ||
| Huw Nash, Chief Officer | ||
| Isabel Aznarez, CoFounder Research | ||
| Eric Rojas, Head Relations | ||
| Thomas Leggett, Chief Officer | ||
| Jason Hoitt, Chief Officer | ||
| Adrian Krainer, Independent CoFounder |
Stoke Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stoke Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (6.13) % | ||||
| Current Valuation | 386.52 M | ||||
| Shares Outstanding | 52.97 M | ||||
| Shares Owned By Insiders | 4.49 % | ||||
| Shares Owned By Institutions | 95.51 % | ||||
| Number Of Shares Shorted | 6.4 M | ||||
| Price To Book | 2.69 X | ||||
| Price To Sales | 37.68 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 0.328 | Quarterly Revenue Growth 0.479 | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.